Sunday, November 24, 2024
Brovana® is a long-acting beta-2 adrenergic agonist (beta-2 agonist) indicated for treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Cipla Limited today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL from the United States Food and Drug Administration (US FDA).
Cipla’s Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL is AN-rated generic therapeutic equivalent version of Sunovion Pharmaceuticals Inc.’s Brovana.
Brovana® is a long-acting beta-2 adrenergic agonist (beta-2 agonist) indicated for:
Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.According to IQVIA (IMS Health), Brovana had US sales of approximately $438M for the 12-month period ending April 2021.
The product is available for shipping immediately.
.jpeg)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)